Skip to content
Enough Ventures

Hard science, chosen for who it serves.

We work in deep tech, nuclear innovation and social impact. The science is hard and the road to market is long, so we choose work where the people who benefit can be named.

Deep tech

Companies built on hard science and engineering, where the advantage is technical, protectable and slow to copy.

We look for cases where the hard problem is real and a first market can be named.

  • AI for scientific discovery
  • Robotics and automation for labs, healthcare and industry
  • Advanced materials and biomaterials
  • Diagnostics and computational biology

Nuclear innovation

Peaceful nuclear science moving out of research institutes and into hospitals, industry and supply chains.

Nuclear research institutes hold science that could serve patients and industry but has not left the institute. We help move it, starting with medicine and isotopes and the automation and safety systems the work depends on.

  • Nuclear medicine and radiopharmaceuticals
  • Isotope supply
  • Automation and remote handling for radiological work
  • Radiation measurement and safety

Social impact

Work whose benefit reaches people beyond those who fund it, in ways that can be shown.

Impact is not a side project or a reporting exercise for us. If we cannot say who is better off and how we would know, we pass.

  • Wider access to care
  • Safer work in high-risk settings
  • More sustainable materials and processes
  • Founders and regions that venture capital overlooks

The question we ask of everything we take on

Who is better off if this works, and can that be shown?

Impact is not a side project or a reporting exercise for us. If we cannot say who is better off and how we would know, we pass.

Three questions decide what we take on

We are most useful early, once the science holds up and before the route to market is settled.

  1. Is the science real and protectable?

    The hard technical work has to hold up under review, and the advantage has to be defensible.

  2. Is there a credible route to market?

    A first buyer, a first use and a path that early capital can actually fund.

  3. Who is better off if it works?

    The benefit should be specific, and there should be a way to show it.

Why now

Four shifts make this the right time.

  • AI is entering the lab

    AI for science is moving from analysis into experimental workflows, instrumentation and decision support.

  • Nuclear medicine is growing

    Nuclear medicine is expanding from diagnosis into targeted therapy, which puts new pressure on isotope supply and handling.

  • Research has to show its reach

    Research institutions are being asked to show that public science reaches the public.

  • Technical judgment is scarce

    Deep-tech investors still depend on scarce technical judgment and the slow work of forming a company.

Working on something that fits?

Tell us what the science is, where it stands and who it would help.